FINWIRES · TerminalLIVE
FINWIRES

SHE:002675

5 stories mentioning SHE:002675Updated just now

Every FINWIRES story that references SHE:002675, newest first.

Asia

Yantai Dongcheng Pharmaceutical Renews German GMP Certificates for Four Raw Materials

Yantai Dongcheng Pharmaceutical (SHE:002675) renewed its good manufacturing practice certificates with the Hamburg Health Authority in Germany for four of its products, according to a Saturday disclosure to the Shenzhen bourse.The products involved include heparin sodium, enoxaparin sodium, nadroparin calcium, and chondroitin sulfate sodium raw materials, the filing said.The certification allows the drugs to be sold within the European Union.

SHE:002675
Asia

Yantai Dongcheng Pharmaceutical Subsidiary Gets Chinese Radioactive Drug Production License

Yantai Dongcheng Pharmaceutical (SHE:002675) subsidiary Nanjing Jiangyuan Andike Positron Research and Development received a radioactive drug production license for its deoxyglucose injection from authorities in Jiangsu, China.The approval will allow the Jilin Changchun Nuclear Medicine Production Center to start producing the drug, according to a Tuesday filing with the Shenzhen bourse.

SHE:002675
Asia

Yantai Dongcheng Pharmaceutical Unit Resubmits Hong Kong IPO Application

Yantai Dongcheng Pharmaceutical (SHE:002675) subsidiary Yantai Lancheng Biotechnology on June 12 resubmitted an application for an H-share initial public offering on the main board of the Hong Kong bourse, according to a Tuesday filing with the Shenzhen bourse.The listing remains subject to approvals from the China Securities Regulatory Commission, Hong Kong Securities and Futures Commission and Hong Kong bourse.Shares of the pharmaceutical company declined 1% in recent trade in Shenzhen.

SHE:002675
Asia

Dongcheng Pharmaceutical Unit's Market Authorization for Nafamostat Gets China Regulatory Acceptance

Yantai Dongcheng Pharmaceutical (SHE:002675) unit Dongcheng North received the acceptance notice issued by China's medical products for the market authorization application for nafamostat mesilate injection.The drug is indicated for disseminated intravascular coagulation and for preventing blood coagulation during extracorporeal circulation in patients with bleeding tendencies, according to a Monday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 1% lower Monday.

SHE:002675
Asia

Yantai Dongcheng Pharmaceutical Unit to Buy Back Minority Stake for Up to 452 Million Yuan

Yantai Dongcheng Pharmaceutical (SHE:002675) unit Andy Center agreed to repurchase a 34.55% stake in Mido (Yantai) Biotechnology for up to 452.3 million yuan.The price includes the 380-million-yuan investment plus 8% annual compound interest from the investment date to the repurchase date.After the buyback, Mido (Yantai) Biotechnology will convert capital reserves to boost Andy Center's registered capital by up to 4.3 million, based on a 1.1-billion-yuan valuation.

SHE:002675

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:002675 in your portfolio
WheelAI
WheelAI
Analyze SHE:002675 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:002675